COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 2 of 5 for:    brigham and women's hospital | Gynecologic Cancer

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03970083
Recruitment Status : Active, not recruiting
First Posted : May 31, 2019
Last Update Posted : March 5, 2020
Information provided by (Responsible Party):
Larissa Lee, MD, Dana-Farber Cancer Institute

Tracking Information
First Submitted Date May 24, 2019
First Posted Date May 31, 2019
Last Update Posted Date March 5, 2020
Actual Study Start Date July 16, 2019
Estimated Primary Completion Date April 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 30, 2019)
Proportion of patients with a tumor oxygen measurement from at least 1 oxygen sensor catheter [ Time Frame: 2 years ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: May 30, 2019)
  • Complete Metabolic Response [ Time Frame: 2 years ]
    Absence of abnormal FDG uptake at the site of abnormal FDG uptake noted on the pre-treatment FDG-PET study
  • Local Tumor Control [ Time Frame: 2 years ]
    Tumor control within the radiation field
  • Disease-Specific Survival [ Time Frame: 2 Years ]
    From start of treatment to time of disease progression or death
  • Overall Survival [ Time Frame: 2 years ]
    From start of treatment until death due to any cause
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
Official Title Quantitative Tumor Oxygen Measurements in Cervical Cancer
Brief Summary This research is studying the level of oxygen in tumors during the brachytherapy procedure.
Detailed Description

Tumors with low levels of oxygen have been found to be more resistant to standard radiation and chemotherapy treatments. For patients with tumors with low oxygen levels, it is not well known if higher radiation doses can overcome treatment resistance to radiation. Currently, there are limited ways of measuring tumor oxygen levels. The investigators believe that measuring tumor oxygen levels during the brachytherapy procedure will allow the investigators to develop better and improved oxygen measurement techniques, and ultimately improve clinical outcomes for patients, such as better local tumor control.

This research study is a Pilot Study, meaning that this is the first time investigators are examining the oxygen sensor being used. This study is designed to test the oxygen sensor's ability to measure the oxygen levels within the participant's cervical tumor with the aid of magnetic resonance imaging (MRI) scans. MRI scans use magnets to make detailed images of the participant's tumor and the surrounding normal tissues during the brachytherapy procedure.

Study Type Observational
Study Design Observational Model: Other
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population All eligible patients will be women with cervical cancer.
  • Gynecologic Cancer
  • Cervical Cancer
Intervention Not Provided
Study Groups/Cohorts Oxygen Levels in Tumors
-Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Active, not recruiting
Actual Enrollment
 (submitted: May 30, 2019)
Original Estimated Enrollment Same as current
Estimated Study Completion Date April 30, 2022
Estimated Primary Completion Date April 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Participants must have a biopsy-proven diagnosis of cervical cancer for which interstitial brachytherapy is planned as standard treatment
  • Age 18 years or older
  • ECOG performance status of 2 or less (see Appendix A)
  • Patients who have received prior radiation or chemotherapy may be enrolled on this study
  • Participant is deemed to be an appropriate candidate for MR-guided brachytherapy by the radiation oncologist and the patient elects to be treated with MR-guided brachytherapy
  • Participant provides informed consent for prospective collection of relevant medical records for analysis of clinical outcome and treatment-planning techniques
  • Ability to understand and the willingness to sign a written informed consent document. Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow- up

Exclusion Criteria:

  • Participants who have a contraindication to MRI identified by the MR procedure screening form, such as a pacemaker, aneurysm clip, inner ear implant, neurostimulator, or other non-MR-compatible device or implant
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Sexes Eligible for Study: Female
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT03970083
Other Study ID Numbers 17-596
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: BCH - Contact the Technology & Innovation Development Office at or email BIDMC - Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at BWH - Contact the Partners Innovations team at DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at MGH - Contact the Partners Innovations team at
Responsible Party Larissa Lee, MD, Dana-Farber Cancer Institute
Study Sponsor Dana-Farber Cancer Institute
Collaborators Not Provided
Principal Investigator: Larissa Lee, MD Brigham and Women's Hospital
PRS Account Dana-Farber Cancer Institute
Verification Date March 2020